Member Info for ThinShins

Comparing with last years version it remains the same.

Offering Statement (Exhibit A) April 17, 2025

"The Founder and Board of Cizzle Biotechnology will provide technical and business support as Board Members or Advisory Committee members of the Company. Additionally, Cizzle Biotechnology PLC will assign its current development and clinical trials program to the Company. In exchange for this exclusive license, the Company will remunerate Cizzle Biotechnology PLC via a 10% royalty on all sales in the USA and Canada. In addition, upon the first to occur of an Equity Financing, an Initial Public Offering or a Liquidation Event by the Company, Cizzle Biotechnology PLC shall be entitled to either (i) participate in the Equity Financing and receive shares pursuant to a defined formula (based on the current Offering, this would result in approximately 1.5% ownership on a fully-diluted basis) or (ii) a success fee of 2% upon a Liquidation Event or an Initial Public Offering (see “Capitalization” section for information as to timing of such equity issuance). "

https://content-archive.fast-edgar.com/20250417/AK2ZG22CZ225MTXZ262H2ZO2NBI9ZZ22ZF72/cizzlebio.pdf

The partners section I referred previously has gone active no longer "404 page not found"

https://cizzlebiotechnology.com/partners/

NEW Social Media Post:

A major leap forward in early cancer diagnosis.

NHS England and the #UK #Government are accelerating cancer diagnosis with the launch of Cancer 360 - a real-time digital platform designed to give GPs access to patient test results within 24 hours of an urgent cancer referral. This transformative tool aims to speed up clinical decision-making and improve outcomes for patients across the #NHS.

By July, the platform is expected to be connected to 75% of NHS trusts, a crucial step towards the UK’s goal of diagnosing 75% of cancers at stage 1 or 2 by 2028.

At Cizzle Biotechnology plc, we’re proud to support the same mission. Our early-stage lung cancer blood test is designed to provide clinicians with vital diagnostic insight, particularly where symptoms are unclear or imaging is inconclusive.

- Earlier detection

- Faster decisions

- Better outcomes

We welcome all innovations that bring us closer to saving lives through earlier cancer detection.

I don’t think my sarcasm in jest came across in that post. All the best

Bold prediction there Techtonic! 😄 I think most of us would agree that without a positive RNS, the share price is likely to drift back down to its usual range, no fancy chart needed for that one!

On the Cizzle website on the about page towards the bottom there is a section "Expanding Global Access"

Through strategic partnerships and licensing, we are unlocking the full potential of our CIZ1B biomarker technology for worldwide use. Our scalable, cost-effective solution is designed for rapid deployment, making early cancer detection more accessible than ever.

Join Us in Shaping the Future of Cancer Diagnostics

We are actively forging partnerships across the healthcare ecosystem, from providers to insurers, to expand access and improve patient outcomes globally.

under this is a button "Partners" which currently brings up a 404 error but something to keep eye out.

Also there is a nice video filmed at iGenomeDx on the "The Science" part of the website.

I've emailed the generic cizzle @ investor-focus . co . uk

Would like to know what the latest is on the China collab last we heard was in Nov 22 and stated "we are now prepared and ready to commence clinical pilot studies".

Not heard anything since?

Could they be the next collaboration announced, given the latest cizzle bio post on X?

https://x.com/cizzlebio/status/1929607557577851317?s=46&t=UyTSUYSWOCZSVVQoHLT0tw

Good job i doubled up on my modest holding few weeks ago when SP was at 1.45p

Your last sentence is extremely out of order, have some shame.

Im not sure this our test if it isn’t ours then a bit disappointing for our chances at commercialisation in the UK.

The reason I’m thinking it’s not ours is because it mentions:

“A pilot scheme in 176 hospitals tested the method in patients with non-small cell lung cancer (NSCLC) – the most common lung cancer. All such patients with stage three and four disease will now be eligible for the tests under the national rollout.

The NHS has just begun offering the tests to around 1,000 women with advanced breast cancer, and will expand this to test for four types of gene mutations – expanding access to targeted treatments.

The technology is also being evaluated for four other cancers, including pancreatic and gallbladder disease, which are some of the hardest to treat.“

Hi Greend100, hopefully with more updates all will be made clear. Atb

The RNS informing us about the collab with iGenomeDX, is a bit vague and the way it reads to me is that iGenomeDX already is COLA/CLIA accredited.

"First COLA and CLIA Accredited Laboratory in USA confirmed"

"·Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, is pleased to announce that its licensing partner Cizzle Bio Inc ("BIO" or "Cizzle Bio") has appointed iGenomeDX, a specialist clinical diagnostics laboratory to launch the Company's first commercial CIZ1B biomarker test in the USA. iGenomeDX is a Commission on Office Laboratory Accreditation ("COLA") accredited and Clinical Laboratory Improvement Amendments ("CLIA") certified clinical laboratory and has been establishing operating and quality systems ahead of offering the test to clinicians for the first time.

iGenoneDX appointed by BIO as first clinical diagnostics laboratory to offer commercial CIZ1B biomarker testing.

· This follows successful collaboration and support between Cizzle, iGenomeDX and BIO to complete an operational and quality systems programme designed to meet the exacting standards required in iGenomeDX's COLA accredited, CLIA certified laboratory, designated to validate CIZ1b as a laboratory developed test for commercial use ahead of the launch of the CIZ1B biomarker test."

To me it seems COLA/CLIA is already in place for this specific lab, so maybe the "slightly extended timeline" to launch isn't due to COLA/CLIA but rather expanding the network and getting additional labs onboard and aligned with COLA/CLIA to "enable a more co-ordinated and comprehensive campaign to roll out the CIZ1B biomarker test."

Could be wrong on this but just the way i interpreted it.

Yesterday marked 4 years since the RTO, where do you all see CIZ being in 2029.

If successful in the launch of the Lung Cancer test and potentially adding to the pipeline for tests for breast cancer, will CIZ have been acquired by another bigger company for example Bio-Techne, Roche, Thermo Fisher etc.?

I believe tradingstar has deleted his account on his own accord, posted on another board today morning.

Signing off

I’ve asked my account to be removed.

Yesterday he started a thread on same board "How to become a good trader ?" he expressed his feelings about his losses and the anxiety he feels.

I hope he is ok seemed very low and disheartened.

Best wishes to all.

Also from yesterdays report:

"In terms of future research, the team at the University of York under the leadership of the Group’s Chief

Scientific Officer, Professor Dawn Coverley will be evaluating how the Group’s CIZ1B biomarker may be

used in point of care devices, and for other types of cancer."

Seems very likely the next test to be added to the portfolio will be Breast Cancer. Considering Prof Dawn's research on it and Cizzles presence at several breast cancer conferences.

At AACR 2025, where innovation meets impact.

Mary Jimenez proudly represented Cizzle Bio, Inc. alongside the Alamo Breast Cancer Foundation and Dr. Daniel Von Hoff, reinforcing our shared commitment to advancing early cancer detection and transforming lives.

https://www.linkedin.com/posts/cizzle-bio-inc_aacr25-cancerresearch-earlydetection-activity-7323095308437962753-b0gF

Website is back up and glad to see a updated fresh new look to it.